

Michael A Caligiuri

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4356619/michael-a-caligiuri-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

131
papers

13,762
citations

50
h-index

117
g-index

139
ext. papers

16,128
ext. citations

10.4
avg, IF

6.67
L-index

#	Paper	IF	Citations
131	Off-the-shelf PSCA-directed chimeric antigen receptor natural killer cell therapy to treat pancreatic cancer.. <i>Gastroenterology</i> , 2022 ,	13.3	5
130	PDGF-D-PDGFR β signaling enhances IL-15-mediated human natural killer cell survival.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022 , 119,	11.5	1
129	Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma.. <i>Blood Cancer Discovery</i> , 2022 , 3, 154-169	7	2
128	A four-stage model for murine natural killer cell development in vivo.. <i>Journal of Hematology and Oncology</i> , 2022 , 15, 31	22.4	0
127	Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19.. <i>Nature Communications</i> , 2022 , 13, 2576	17.4	3
126	The K18-hACE2 Transgenic Mouse Model Recapitulates Non-Severe and Severe COVID-19 in Response to Infectious Dose of SARS-CoV-2 Virus. <i>Journal of Virology</i> , 2021 , JVI0096421	6.6	8
125	An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma. <i>Nature Communications</i> , 2021 , 12, 5908	17.4	6
124	Targeting Fc Receptor-Mediated Effects and the "Don't Eat Me" Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer. <i>Clinical Cancer Research</i> , 2021 ,	12.9	2
123	An Oncolytic Virus Expressing IL15/IL15R α Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma. <i>Cancer Research</i> , 2021 , 81, 3635-3648	10.1	18
122	Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2021 , 138, 1465-1480	2.2	7
121	The RNA m6A reader YTHDF2 controls NK cell antitumor and antiviral immunity. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	18
120	Improving Goal Concordant Care Among 10 Leading Academic U.S. Cancer Hospitals: A Collaboration of the Alliance of Dedicated Cancer Centers. <i>Oncologist</i> , 2021 , 26, 533-536	5.7	1
119	Enhancing Effects of Environmental Enrichment on the Functions of Natural Killer Cells in Mice. <i>Frontiers in Immunology</i> , 2021 , 12, 695859	8.4	2
118	Enriched environment enhances NK cell maturation through hypothalamic BDNF in male mice. <i>European Journal of Immunology</i> , 2021 , 51, 557-566	6.1	5
117	Oncolytic HSV Vectors and Anti-Tumor Immunity. <i>Current Issues in Molecular Biology</i> , 2021 , 41, 381-468	2.9	3
116	Unraveling the Role of Innate Lymphoid Cells in Acute Myeloid Leukemia. <i>Cancers</i> , 2021 , 13,	6.6	2
115	Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses. <i>Cell Reports Medicine</i> , 2021 , 2, 100189	18	80

114	Hijacking TYRO3 from Tumor Cells via Trogocytosis Enhances NK-cell Effector Functions and Proliferation. <i>Cancer Immunology Research</i> , 2021 , 9, 1229-1241	12.5	2
113	Environmental activation of a hypothalamic BDNF-adipocyte IL-15 axis regulates adipose-natural killer cells. <i>Brain, Behavior, and Immunity</i> , 2021 , 95, 477-488	16.6	1
112	Acute Myeloid Leukemia Alters Group 1 Innate Lymphoid Cell Differentiation from a Common Precursor. <i>Journal of Immunology</i> , 2021 , 207, 1672-1682	5.3	1
111	Cbl-b Is Upregulated and Plays a Negative Role in Activated Human NK Cells. <i>Journal of Immunology</i> , 2021 , 206, 677-685	5.3	2
110	CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma. <i>JCI Insight</i> , 2021 , 6,	9.9	4
109	Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 168	22.4	51
108	Combined loss of function of two different loci of miR-15/16 drives the pathogenesis of acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 12332-12340	11.5	16
107	Oncolytic HSV-Infected Glioma Cells Activate NOTCH in Adjacent Tumor Cells Sensitizing Tumors to Gamma Secretase Inhibition. <i>Clinical Cancer Research</i> , 2020 , 26, 2381-2392	12.9	13
106	Role of Mir-29b in T-Cell Development and in Cutaneous T-Cell Lymphoma Pathogenesis. <i>Blood</i> , 2020 , 136, 37-37	2.2	
105	Activated Natural Killer Cells Are Associated with Poor Clinical Prognosis in High-Risk B- and T- Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2020 , 136, 39-39	2.2	
104	CSF1R inhibitor PLX5622 and environmental enrichment additively improve metabolic outcomes in middle-aged female mice. <i>Aging</i> , 2020 , 12, 2101-2122	5.6	12
103	Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with an endemic human CoV 2020 ,		14
102	Notch Regulates Innate Lymphoid Cell Plasticity during Human NK Cell Development. <i>Journal of Immunology</i> , 2020 , 205, 2679-2693	5.3	8
101	A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2019 , 25, 4955-4965	12.9	16
100	Adipocytes: A Novel Target for IL-15/IL-15R α Cancer Gene Therapy. <i>Molecular Therapy</i> , 2019 , 27, 922-932	11.7	19
99	Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. <i>Nature</i> , 2019 , 572, 254-259	50.4	131
98	The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector. <i>Cancer Discovery</i> , 2019 , 9, 1422-1437	24.4	90
97	FLT3-ITD Activates Cytoplasmic Drosha-Dependent Non-Canonical Mechanisms of Mir-155 Biogenesis in Acute Myeloid Leukemia. <i>Blood</i> , 2019 , 134, 2722-2722	2.2	

96	CSIG-23. NOTCH ACTIVATION INDUCED BY HSV-1 ENCODED miRNA-H16 SENSITIZES oHSV-TREATED TUMORS TO NOTCH INHIBITOR. <i>Neuro-Oncology</i> , 2019 , 21, vi49-vi49	1	78
95	Cellular pathways in the development of human and murine innate lymphoid cells. <i>Current Opinion in Immunology</i> , 2019 , 56, 100-106	7.8	30
94	The IL-15-AKT-XBP1s signaling pathway contributes to effector functions and survival in human NK cells. <i>Nature Immunology</i> , 2019 , 20, 10-17	19.1	42
93	Enriched environment regulates thymocyte development and alleviates experimental autoimmune encephalomyelitis in mice. <i>Brain, Behavior, and Immunity</i> , 2019 , 75, 137-148	16.6	23
92	Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone. <i>Clinical Cancer Research</i> , 2018 , 24, 3273-3281	12.9	16
91	Complex role of NK cells in regulation of oncolytic virus-bortezomib therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 4927-4932	11.5	37
90	Patient Enrichment for Precision-Based Cancer Clinical Trials: Using Prospective Cohort Surveillance as an Approach to Improve Clinical Trials. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 23-26	6.1	9
89	A novel regimen for relapsed/refractory adult acute myeloid leukemia using a partial tandem duplication targeted therapy: results of phase 1 study NCI 8485. <i>Haematologica</i> , 2018 , 103, 982-987	6.6	11
88	Molecular Basis for the Recognition of Herpes Simplex Virus Type 1 Infection by Human Natural Killer Cells. <i>Frontiers in Immunology</i> , 2018 , 9, 183	8.4	12
87	An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma. <i>Nature Biotechnology</i> , 2018 ,	44.5	36
86	Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. <i>Journal of Immunology</i> , 2018 , 200, 565-572	5.3	18
85	SMAD4 promotes TGF- β -independent NK cell homeostasis and maturation and antitumor immunity. <i>Journal of Clinical Investigation</i> , 2018 , 128, 5123-5136	15.9	41
84	Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. <i>Blood</i> , 2018 , 132, 1792-1804	2.2	46
83	CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway. <i>Immunity</i> , 2018 , 49, 464-476.e4	32.3	57
82	A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma. <i>Cancer Immunology Research</i> , 2018 , 6, 776-787	12.5	50
81	Amplification of mixed lineage leukemia gene perturbs hematopoiesis and cooperates with partial tandem duplication to induce acute myeloid leukemia. <i>Haematologica</i> , 2017 , 102, e300-e304	6.6	1
80	Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 312-322	6.1	59
79	IL-18 Drives ILC3 Proliferation and Promotes IL-22 Production via NF- κ B. <i>Journal of Immunology</i> , 2017 , 199, 2333-2342	5.3	46

78	The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells. <i>Immunity</i> , 2017 , 47, 159-170.e10	32.3	19
77	The Broad Spectrum of Human Natural Killer Cell Diversity. <i>Immunity</i> , 2017 , 47, 820-833	32.3	302
76	BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection-Implications for Oncolytic Viral Therapy. <i>Clinical Cancer Research</i> , 2017 , 23, 1809-1819	12.9	20
75	Modeling Human Natural Killer Cell Development in the Era of Innate Lymphoid Cells. <i>Frontiers in Immunology</i> , 2017 , 8, 360	8.4	70
74	Biallelic mutations in IRF8 impair human NK cell maturation and function. <i>Journal of Clinical Investigation</i> , 2017 , 127, 306-320	15.9	53
73	Ibrutinib treatment improves T cell number and function in CLL patients. <i>Journal of Clinical Investigation</i> , 2017 , 127, 3052-3064	15.9	197
72	Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16 Suppl, S181-S190.e4	2	5
71	Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma. <i>Cancer Discovery</i> , 2016 , 6, 986-1005	24.4	52
70	Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment. <i>Cancer Research</i> , 2016 , 76, 2125-36	10.1	121
69	MicroRNA-29b mediates altered innate immune development in acute leukemia. <i>Journal of Clinical Investigation</i> , 2016 , 126, 4404-4416	15.9	42
68	NKp80 Defines a Critical Step during Human Natural Killer Cell Development. <i>Cell Reports</i> , 2016 , 16, 379-396	15.9	68
67	Obesity, Inflammation, and Cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2016 , 11, 421-493	15.9	381
66	Environmental and Genetic Activation of Hypothalamic BDNF Modulates T-cell Immunity to Exert an Anticancer Phenotype. <i>Cancer Immunology Research</i> , 2016 , 4, 488-497	12.5	35
65	A Progenitor Cell Expressing Transcription Factor ROR γ Generates All Human Innate Lymphoid Cell Subsets. <i>Immunity</i> , 2016 , 44, 1140-50	32.3	125
64	Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts. <i>Blood</i> , 2016 , 127, 2879-89	2.2	63
63	CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. <i>Scientific Reports</i> , 2015 , 5, 11483	4.9	189
62	Transcription factor Foxo1 is a negative regulator of natural killer cell maturation and function. <i>Immunity</i> , 2015 , 42, 457-70	32.3	102
61	The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells. <i>Journal of Immunology</i> , 2015 , 195, 1995-2005	5.3	24

60	Promoter-Specific Hypomethylation Is Associated with Overexpression of PLS3, GATA6, and TWIST1 in the Sezary Syndrome. <i>Journal of Investigative Dermatology</i> , 2015 , 135, 2084-2092	4.3	27
59	TGF β Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response. <i>Cancer Research</i> , 2015 , 75, 5273-82	10.1	61
58	Rapid Column-Free Enrichment of Mononuclear Cells from Solid Tissues. <i>Scientific Reports</i> , 2015 , 5, 12490	4.9	7
57	The Epstein-Barr Virus Lytic Protein BZLF1 as a Candidate Target Antigen for Vaccine Development. <i>Cancer Immunology Research</i> , 2015 , 3, 787-94	12.5	14
56	PTEN is a negative regulator of NK cell cytolytic function. <i>Journal of Immunology</i> , 2015 , 194, 1832-40	5.3	28
55	Human natural killer cell development in secondary lymphoid tissues. <i>Seminars in Immunology</i> , 2014 , 26, 132-7	10.7	85
54	The transcription Factor AHR prevents the differentiation of a stage 3 innate lymphoid cell subset to natural killer cells. <i>Cell Reports</i> , 2014 , 8, 150-62	10.6	65
53	The natural product phyllanthusin C enhances IFN- γ production by human NK cells through upregulation of TLR-mediated NF- κ B signaling. <i>Journal of Immunology</i> , 2014 , 193, 2994-3002	5.3	35
52	Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells. <i>Blood</i> , 2014 , 124, 1127-35	2.2	41
51	Molecular pathways: interleukin-15 signaling in health and in cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 2044-50	12.9	118
50	The Epstein-Barr Virus Lytic Protein BZLF1 As a Candidate Target Antigen for Vaccine Development. <i>Blood</i> , 2014 , 124, 4144-4144	2.2	
49	Location and cellular stages of natural killer cell development. <i>Trends in Immunology</i> , 2013 , 34, 573-82	14.4	222
48	Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias. <i>Blood</i> , 2012 , 120, 1130-6	2.2	62
47	A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. <i>Blood</i> , 2012 , 120, 4324-33	2.2	193
46	Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. <i>Cancer Cell</i> , 2012 , 22, 645-55	24.3	115
45	NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. <i>Nature Medicine</i> , 2012 , 18, 1827-34	50.5	142
44	Evidence for a stepwise program of extrathymic T cell development within the human tonsil. <i>Journal of Clinical Investigation</i> , 2012 , 122, 1403-15	15.9	65
43	The Clinical Role of Micronas (miRs) in Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): miR-155 Upregulation Independently Identifies High-Risk Patients (Pts). <i>Blood</i> , 2012 , 120, 1387-1387	2.2	1

42	Human Natural Killer (NK) Cells: Differential Expression of Phosphatase and Tensin Homologue Deleted On Chromosome Ten (PTEN) During NK Cell Development Regulates Its Cytolytic Activity Against Leukemic Target Cells. <i>Blood</i> , 2012 , 120, 254-254	2.2	
41	NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human. <i>Journal of Clinical Investigation</i> , 2011 , 121, 1456-70	15.9	51
40	MLL-PTD Causes Hypomorph Condition of CBF Complex (RUNX1/CBF) and Predisposes the Abnormal Hematopoietic Stem and Progenitor Cells (HSPCs) to Clonal Expansion. <i>Blood</i> , 2011 , 118, 2801-2801	2.2	
39	Activation of a Mir-181-Targeting HOXA-PBX3 Homeobox Gene Signature Is Associated with Adverse Prognosis of Cytogenetically Abnormal Acute Myeloid Leukemia. <i>Blood</i> , 2011 , 118, 236-236	2.2	
38	In vivo role of Flt3 ligand and dendritic cells in NK cell homeostasis. <i>Journal of Immunology</i> , 2010 , 184, 2769-75	5.3	40
37	CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. <i>Blood</i> , 2010 , 115, 274-81	2.2	180
36	A novel mouse model for the aggressive variant of NK cell and T cell large granular lymphocyte leukemia. <i>Leukemia Research</i> , 2010 , 34, 203-9	2.7	15
35	Interleukin-1beta selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue. <i>Immunity</i> , 2010 , 32, 803-14	32.3	167
34	Effective Targeting of Acute Myeloid Leukemia (AML) Harboring the FLT3 ITD Mutation through the Axl/Gas6 Pathway. <i>Blood</i> , 2010 , 116, 500-500	2.2	1
33	The Axl/Gas6 pathway is required for optimal cytokine signaling during human natural killer cell development. <i>Blood</i> , 2009 , 113, 2470-7	2.2	49
32	Stage 3 immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH 17 cytokine interleukin-22. <i>Blood</i> , 2009 , 113, 4008-10	2.2	106
31	Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. <i>Blood</i> , 2009 , 114, 2667-77	2.2	305
30	Human natural killer cells. <i>Blood</i> , 2008 , 112, 461-9	2.2	1261
29	TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. <i>Journal of Immunology</i> , 2008 , 181, 3784-92	5.3	158
28	Characterization of An NKp46+ NKT Subset Which Is Susceptible to Malignant Transformation in Vivo.. <i>Blood</i> , 2008 , 112, 1546-1546	2.2	
27	Evidence for discrete stages of human natural killer cell differentiation in vivo. <i>Journal of Experimental Medicine</i> , 2006 , 203, 1033-43	16.6	327
26	Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. <i>Immunity</i> , 2006 , 24, 575-90	32.3	189
25	Human natural killer cell development. <i>Immunological Reviews</i> , 2006 , 214, 56-72	11.3	362

24	NK Cells Contribute Significantly to the Innate Immune Effector Role of CD37-Specific SMIP in CLL and NHL.. <i>Blood</i> , 2006 , 108, 135-135	2.2	3
23	A Phase II Study of the TNF- α Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities.. <i>Blood</i> , 2006 , 108, 2841-2841	2.2	4
22	A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. <i>Immunity</i> , 2005 , 22, 295-304	32.3	288
21	Interleukin-2, interleukin-15, and their roles in human natural killer cells. <i>Advances in Immunology</i> , 2005 , 86, 209-39	5.6	228
20	ReSETting PP2A Tumor Suppressor Activity Overcomes BCR/ABL Leukemogenic Potential in Blast Crisis CML.. <i>Blood</i> , 2005 , 106, 1992-1992	2.2	
19	Immunotherapeutic approaches for hematologic malignancies. <i>Hematology American Society of Hematology Education Program</i> , 2004 , 2004, 337-53	3.1	24
18	Elucidation of the Molecular Mechanisms by Which Inflammatory and Anti-Inflammatory Monokines Regulate Interferon (IFN)- γ Production.. <i>Blood</i> , 2004 , 104, 111-111	2.2	2
17	Efficient and Reproducible Retroviral Infection of Primary Human Natural Killer Cells.. <i>Blood</i> , 2004 , 104, 1348-1348	2.2	
16	Select High Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy with Fludarabine and Rituximab in Chronic Lymphocytic Leukemia (CLL): Preliminary Justification for Risk-Adapted Therapy.. <i>Blood</i> , 2004 , 104, 476-476	2.2	3
15	A Phase II Study of the TNF- α Inhibitor Etanercept and Thrice Weekly Rituximab: Evidence of Clinical Activity in the Absence of del(17p13.1) Genomic Abnormalities.. <i>Blood</i> , 2004 , 104, 3469-3469	2.2	1
14	Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. <i>Journal of Immunology</i> , 2002 , 169, 4279-87	5.3	494
13	In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. <i>Blood</i> , 2002 , 100, 3633-8	2.2	341
12	Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. <i>Blood</i> , 2002 , 100, 1935-47	2.2	405
11	Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. <i>European Journal of Immunology</i> , 2001 , 31, 3016-25	6.1	129
10	Interleukin 15: biology and relevance to human disease. <i>Blood</i> , 2001 , 97, 14-32	2.2	758
9	The biology of human natural killer-cell subsets. <i>Trends in Immunology</i> , 2001 , 22, 633-40	14.4	2075
8	Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. <i>Journal of Experimental Medicine</i> , 2001 , 193, 219-31	16.6	292
7	Ontogeny and expansion of human natural killer cells: clinical implications. <i>International Reviews of Immunology</i> , 2001 , 20, 503-34	4.6	26

6	Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. <i>Blood</i> , 2001 , 97, 3146-51	2.2	1023
5	Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2 / neu-positive breast cancer cells 2001 , 31, 3016		3
4	Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology. <i>Cancer Investigation</i> , 2000 , 18, 768-80	2.1	43
3	Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene. <i>Oncogene</i> , 1999 , 18, 3159-65	9.2	45
2	A review of the association between interleukin-10 and human B-cell malignancies. <i>Cancer Immunology, Immunotherapy</i> , 1998 , 46, 239-44	7.4	50
1	The RNA m6A reader YTHDF2 controls NK cell anti-tumor and anti-viral immunity		1